Literature DB >> 21258194

[The role of NF-kappaB in colon cancer].

Geom Seog Seo1.   

Abstract

Colon cancer is the 3rd common malignancy and 4th common cause of cancer death in Korea. Recent studies have shown that abnormal inflammatory response plays a critical role in colon carcinogenesis. A striking example of connection between inflammation and cancer is NF-kappaB, in which key regulator of inflammation and immune response is associated with target for colon cancer treatment. Constitutive NF-kappaB expression in colon cancer is 40-80% in vivo as well as in vitro, and the inactivation of IKKbeta subunit can reduce tumor multiplicity. The possible mechanisms by which NF-kappaB can contribute to colon carcinogenesis include the activator of antiapoptotic gene expression, enhanced cell survival and proliferation, regulation of angiogenesis and promotion of metastasis of cancer cells. Recent insights into the role of NF-kappaB involved in colon cancer development as well as their relevance as therapeutic targets are herein discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21258194     DOI: 10.4166/kjg.2011.57.1.3

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  3 in total

1.  Tripartite motif 52 (TRIM52) promotes proliferation, migration, and regulation of colon cancer cells associated with the NF-κB signaling pathway.

Authors:  Yanjiao Guo; Yiming Zhou; Xiaodong Gu; Jianbin Xiang
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  Updates from the Intestinal Front Line: Autophagic Weapons against Inflammation and Cancer.

Authors:  Federica Madia; Valentina Grossi; Alessia Peserico; Cristiano Simone
Journal:  Cells       Date:  2012-08-21       Impact factor: 6.600

3.  Mast cell modulates tumorigenesis caused by repeated bowel inflammation condition in azoxymethane/dextran sodium sulfate-induced colon cancer mouse model.

Authors:  Ji-Hyun Lee; Yong-Deok Jeon; Mingjie Xin; Ji-Ye Lim; Young-Mi Lee; Dae-Ki Kim
Journal:  Biochem Biophys Rep       Date:  2022-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.